Advanced in Familial Wilms Tumor 2

Dr. Kathryn A. Bylow

Hematology Oncology | Geriatrics | Hematology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Accepting New Patients
Offers Telehealth
Advanced in Familial Wilms Tumor 2
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathryn Bylow is a Hematologist Oncology specialist and a Geriatrics provider in Milwaukee, Wisconsin. Dr. Bylow is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Liver Embolization, and Gastrostomy. Dr. Bylow is currently accepting new patients.

Her clinical research consists of co-authoring 11 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Geriatrics
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: September 22, 2023
Intervention Type: Other, Drug
Study Drugs: Standard of care ADT, HMB, Arginine, Glutamine
Study Phase: Phase 2
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

11 Total Publications

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 23, 2025
Similar Doctors
Distinguished in Familial Wilms Tumor 2
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology
Distinguished in Familial Wilms Tumor 2
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology

City Of Hope Medical Group Of Illinois PLLC

2520 Elisha Ave, 
Zion, IL 
 (42.3 miles away)
847-872-4561
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients

Walter Stadler is a Hematologist Oncology specialist and a Hematologist in Zion, Illinois. Dr. Stadler is rated as an Elite provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Orchiectomy, and Nephrectomy. Dr. Stadler is currently accepting new patients.

Distinguished in Familial Wilms Tumor 2
Dr. Christos E. Kyriakopoulos
Hematology Oncology | Hematology | Oncology
Distinguished in Familial Wilms Tumor 2
Dr. Christos E. Kyriakopoulos
Hematology Oncology | Hematology | Oncology

University Of Wisconsin Medical Foundation Inc

250 Doctors Ct, 
Johnson Creek, WI 
 (37.5 miles away)
920-699-3500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christos Kyriakopoulos is a Hematologist Oncology specialist and a Hematologist in Johnson Creek, Wisconsin. Dr. Kyriakopoulos is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Kyriakopoulos is currently accepting new patients.

Distinguished in Familial Wilms Tumor 2
Dr. Emily G. Robinson
Hematology Oncology | Hematology | Oncology
Distinguished in Familial Wilms Tumor 2
Dr. Emily G. Robinson
Hematology Oncology | Hematology | Oncology

Mercy Health System Corporation

1000 Mineral Point Ave, 
Janesville, WI 
 (56.8 miles away)
608-756-6000
Languages Spoken:
English
See accepted insurances

Emily Robinson is a Hematologist Oncology specialist and a Hematologist in Janesville, Wisconsin. Dr. Robinson is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Desmoplastic Small Round Cell Tumor, Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bylow's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile